|
Median age, years (range)
|
71 (49–86)
|
|---|
|
Gender Male/female
|
19/25
|
|
Performance status
| |
|
0
|
24 (54.5)
|
|
1
|
14 (31.8)
|
|
2
|
4 (9.1)
|
|
≥3
|
2 (4.5)
|
|
Type of M protein n (%)
| |
|
IgG
|
22 (50.0)
|
|
IgA
|
10 (22.7)
|
|
IgD
|
1 (2.3)
|
|
BJP
|
10 (22.7)
|
|
No secreted
|
1 (2.3)
|
|
Durie-Salmon stage n (%)
| |
|
I
|
4 (9.1)
|
|
II
|
6 (13.6)
|
|
III
|
34 (77.3)
|
|
ISS stage n (%)
| |
|
1
|
10 (22.7)
|
|
2
|
11 (25.0)
|
|
3
|
23 (52.3)
|
|
No. genetic abnormalities of 13q deletion n (%)
| |
|
Yes
|
6 (13.6)
|
|
No
|
38 (86.4)
|
|
No. of stem cell transplantation n (%)
| |
|
Yes
|
15 (34.1)
|
|
No
|
29 (65.9)
|
|
No. of prior treatment regimens* n (%) 09 (20.5)
| |
|
1
|
16 (36.4)
|
|
2
|
7 (15.9)
|
|
≥3
|
12 (27.3)
|
|
Type of prior treatment regimens n (%)
| |
|
VAD
|
22 (25.9)
|
|
MP
|
19 (22.4)
|
|
HDD
|
10 (11.8)
|
|
Thalidomide
|
9 (10.6)
|
|
Stem cell transplantation
|
5 (5.9)
|
|
CP
|
5 (5.9)
|
|
ROAD
|
4 (4.7)
|
|
Cyclophosphamide alone
|
3 (3.5)
|
|
DEX pulse
|
2 (2.4)
|
|
MD
|
2 (2.4)
|
|
INF α-MP
|
2 (2.4)
|
|
CAD
|
1 (1.2)
|
|
RD
|
1 (1.2)
|
- CP: cyclophosphamide, prednisolone; CAD: cyclophosphamide, adriamycin, dexamethasone; DEX pulse: dexamethasone pulse therapy; MD: melphalan, dexamethasone; MP: melphalan, prednisolone; HDD: high dose dexamethasone; INF α: Interferon Alpha, RD: lenalidomide, dexamethasone; ROAD: MCNU, vincristine, melphalan, dexamethasone; VAD: vincristine, adriamycin, dexamethasone.
- *A regimen was defined as a single drug or combination therapy. Front-line therapy could be composed of more than one regimen.
